Serving the PF Community

Call 844.TalkPFF (844.825.5733) to speak with a representative today. LEARN MORE

NEW Patient and Caregiver Survey

Your survey results will impact future PF disease education, awareness, and research programs. LEARN MORE

Thank You to the PF Community

  You made Global Pulmonary Fibrosis Awareness Month a great success! MORE

Invest in the PF Community

Your donation brings us one step closer to a cure for PF. LEARN MORE
We Imagine a World Without
Pulmonary Fibrosis

The mission of the Pulmonary Fibrosis Foundation (PFF) is to serve as the trusted resource for the pulmonary fibrosis (PF) community by raising awareness, providing disease education, and funding research.


Speak to a professional 

Health care professional resources available. Call or email the PFF Patient Communication Center.

Info about the pcc 

Let the world know

Host an event, engage legislators, or distribute educational materials during Global PF Awareness Month.

Get  Involved

Honor a loved one

Create an online tribute page to honor the memory of a loved one or show your support for a friend.

Ways to Give
 
Announcements
  • PFF SUBMITS SURVEY DATA FROM MORE THAN 1,100 PULMONARY FIBROSIS PATIENTS AND FAMILIES TO US FDA FOR UPCOMING DRUG DEVELOPMENT MEETING

    The Pulmonary Fibrosis Foundation (PFF) announced today that it has submitted survey data from more than 1,100 patients and families suffering from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis on September 26.

  • SEPTEMBER IS GLOBAL PULMONARY FIBROSIS AWARENESS MONTH

    The Pulmonary Fibrosis Foundation launches a full month of events and initiatives for September's Global Pulmonary Fibrosis (PF) Awareness Month, starting with a proclamation by Chicago's mayor; surpassing a milestone in collecting PF patient and caregiver survey data; and the pulmonary fibrosis community embracing PF social media.

  • ROCHE AND INTERMUNE, INC. REACH DEFINITIVE MERGER AGREEMENT

    “The merger of Roche and InterMune is an exciting step forward for the fibrosis community. The combined resources and commitment to patients with pulmonary disease of both Roche and InterMune will likely improve the care of patients with pulmonary fibrosis and accelerate the identification of additional novel therapies for fibrotic lung disease,” said Gregory P. Cosgrove, MD, Chief Medical Officer of the Pulmonary Fibrosis Foundation.

  • PULMONARY FIBROSIS FOUNDATION'S PATIENT SURVEY TO REVEAL NEW INSIGHTS

    The Pulmonary Fibrosis Foundation (PFF) today announced that it has funded a survey designed to collect patient insights, which will help inform decision makers with a better understanding of pulmonary fibrosis (PF).

More Announcements >>
Events
More Events >>

Footer_Ad_TeamPFF

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >